🇺🇸 FDA
Patent

US 11220501

Solid forms of {6-[(2-amino-3-chloropyridin-4-yl)sulfanyl]-3-[(3S,4S)-4-amino-3-methyl-2-oxa-8- azaspiro[4.5]decan-8-yl]-5-methylpyrazin-2-yl} methanol, a SHP2 inhibitor

granted A61PA61P35/00

Quick answer

US patent 11220501 (Solid forms of {6-[(2-amino-3-chloropyridin-4-yl)sulfanyl]-3-[(3S,4S)-4-amino-3-methyl-2-oxa-8- azaspiro[4.5]decan-8-yl]-5-methylpyrazin-2-yl} methanol, a SHP2 inhibitor) held by Revolution Medicines, Inc. expires Mon Jan 06 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Revolution Medicines, Inc.
Grant date
Tue Jan 11 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 06 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
33
CPC classes
A61P, A61P35/00